TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00325949
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 tablets BID
Study: NCT02216669
Drug: DTP348
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive a continuous oral dose of DTP348 for 7 days per week for 7 weeks
Study: NCT01609348
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule matching active drug to be taken once a day for 12 weeks
Study: NCT02847702
Drug: VM902A 400-mg Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taken orally with food twice daily
Study: NCT02847702
Drug: Naproxen 500-mg Capsules
Normalized name: naproxen 500 MG
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Taken orally with food twice daily
Study: NCT02847702
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules to match VM902A and/or naproxen taken orally with food twice daily
Study: NCT01122901
Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT01998906
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60 mg/m2 IV on Day 1 of Cycles 1 through 3
Study: NCT01998906
Drug: CMF
Normalized name: Cyclophosphamide, Methotrexate, and Fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMF: Cyclophosphamide (600 mg/m2 IV bolus), methotrexate (40 mg/m2 IV bolus), 5-fluorouracil (600 mg/m2 IV bolus) on Day 1 of Cycles 8 through 10
Study: NCT00428519
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for 14 days
Study: NCT01061203
Drug: Grazax
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with 75.000 SQ-T once daily
Study: NCT01061203
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet with no active grass component.
Study: NCT00473902
Drug: Creatine Monohydrate, Conjugated Linoleic Acid
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02473419
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00477776
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 10 mg 3 times a day for 7 days, 2 times a day from day 8 to 10, once a day from day 11 to 12
Study: NCT00886951
Drug: I123MNI388/I123MNI390
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be dosed by intravenous injection up to 5 mCi and not to exceed 5.5 (not \>10% of 5 mCi limit) 123-I MNI-388 or 123-I MNI-390.
Study: NCT02403596
Drug: Exacyl®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00761709
Drug: AL-39256 Ophthalmic Suspension, 1%
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00761709
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive ingredients used as a placebo comparator
Study: NCT01185782
Drug: Gonalef® (Follitropin alfa)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous administration of follitropin alfa at a dose of 75 IU/day was started on dosing Day 1 and the same daily dose was maintained for the first 7 days of the treatment period. Dose increment by 37.5 IU was permitted on dosing Day 8, Day 15 and Day 22 if the dosage increase criterion was met.
Study: NCT01351493
Drug: Nitric Oxide
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitric Oxide Gel, once or twice per day, 12weeks
Study: NCT01351493
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo Gel, once or twice per day, 12weeks
Study: NCT00648544
Drug: Pravastatin
Normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose 80 mg oral immediate-release tablet
Study: NCT00648544
Drug: Pravastatin
Normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose 80 mg oral immediate-release tablets
Study: NCT01447654
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg for 12 months.
Study: NCT04046328
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric-Coated Delayed Release Placebo Capsules
Study: NCT04032067
Drug: GV1001 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9 % Normal Saline
Study: NCT04032067
Drug: Proscar placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: PO
Study: NCT00004164
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00004164
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04412577
Drug: TQB3473
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQB3473 tablets administered orally once. Then TQB3473 tablets administered orally, once daily in 28-day cycle after 3 days of first administration.
Study: NCT01138423
Drug: Placebo (for aliskiren)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily treatment with placebo tablets for 8-weeks, according to the following regiment: once daily (morning time) 1 tablet during the first 2 weeks, followed by once daily (morning time) 2 tablets during the remaining 6 weeks. Coincidental intake of grapefruit(juice) should be avoided. This treatment interval is followed by a one-week tapering period: 1 tablet on day 1, 2, 3, 4, 5 and 7.
Study: NCT01609491
Drug: norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: If the mean arterial pressure drops below 20% of the baseline value and/or below 90 mmHg, a syringe pump with norepinephrine (depending on randomisation) will be started. The anaesthetist will be blinded for the type of vasopressor. Concentrations Norepinephrine (10 µg/ml) will be used in the syringes
Study: NCT00865436
Drug: CLUCOVANCE® 5 mg/500 mg Tablets, single dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under fasting conditions
Study: NCT00171184
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet once daily with sham titration
Study: NCT01860664
Drug: hydrocortisone ophthalmic ointment 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Patients will be instructed to apply Hydrocortisone Ophthalmic Ointment 0.5% or placebo in the lower cul de sac or lid margin BID~* Patients will be instructed to not use the study medications at least 2 hours prior to their appointment.~* Study medication dosing details:~  * 0.05 grams hydrocortisone per gram of combination product~ * each application equal to 1/20th of a gram~ * total amount of active ingredient applied to each eye per application = 0.0025 grams hydrocortisone~ * total amount hydrocortisone applied per eye per day = 0.005 grams hydrocortisone~ * Total amount of active ingredient applied per eye throughout duration of the two week study = 0.07 grams hydrocortisone
Study: NCT01860664
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mineral oil and white petrolatum
Study: NCT01852071
Drug: PEG-ADA ERT
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG-ADA ERT is discontinued at Day +30 (-3/+15 days) after successful engraftment
Study: NCT02735239
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: orally-administered chemotherapy
Study: NCT02735239
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: chemo-protective agent
Study: NCT00240929
Drug: MEDI-493
Normalized name: Medi-Lyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active Comparator
Study: NCT00017225
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00017225
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00017225
Drug: tretinoin
Normalized name: Tretinoin
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02432911
Drug: CAG regimen (Aclacinomycin, cytarabine, with/w/o G-CSF)
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aclacinomycin 20mg/d for 4 days combined with cytarabine 20mg bid for 10 days with/without G-CSF 6ug/m2 from 1 day before therapy to day 10 of therapy.
Study: NCT03833336
Drug: Ferroglycine Sulfate
Normalized name: SULFATE
DrugBank: Sulfate ion (DB14546)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One group assigned to receive oral iron will receive two 100 mg oral capsule of ferroglycine sulfate plus intravenous placebo (normal saline solution)
Study: NCT03833336
Drug: Sucrosomial Iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: One group assigned to receive oral iron will receive or two oral capsule containing 30 mg of pyrophosphate sucrosomial iron plus intravenous placebo (normal saline solution)
Study: NCT03963336
Drug: LMWH
Normalized name: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous LMWH 1mg/kg/day for 2 weeks
Study: NCT02214160
Drug: UX007
Normalized name: UX007
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally (PO) with food or by gastrostomy tube, at the target dose range of 25-35% of total calories.
Study: NCT04113096
Drug: Dibenzyl trisulphide capsules
Normalized name: dibenzyl ether
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg once daily for 6 months
Study: NCT04113096
Drug: Stage IV Breast Cancer Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg once daily for 6 months
Study: NCT04113096
Drug: Stage IV: Colon Cancer Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg once daily for 6 months
Study: NCT04113096
Drug: Cervical Cancer Stage IV Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg once daily for 6 months
Study: NCT04113096
Drug: Cancer of the Prostate Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg once daily for 6 months
Study: NCT02191319
Drug: Viramune®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00739141
Drug: fludarabine, cyclophosphamide, thiotepa, radiation therapy, unrelated donor umbilical cord blood graft
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide 50 mg/kg/dose x 1 IV day -6 (1 dose) Fludarabine 30 mg/m2/dose x 5 IV days -6 to -2 (5 doses) Thiotepa 5 mg/kg/dose x 2 IV days -5 to -4 (2 doses) TBI 200 cGy/dose x 2 days -2 to -1 (2 doses). On transplant day, the cord blood cells will be given through your catheter. The immune suppressing drugs you will receive are called cyclosporine-A (CSA) and mycophenolate mofetil (MMF). These will be started 3 days before the transplant and will be given through your catheter. Later they can be given as tablets.
Study: NCT03754959
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Film-coated tablet
Study: NCT01571167
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive varenicline or matched placebo from day 1 through day 7, then the same subjects will return within 2-4 weeks and assigned to each of the two remaining study medication conditions, and undergo the identical procedures (3-phase study).
Study: NCT01784211
Drug: LY2605541
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01408849
Drug: Maytenus ilicifolia leaves infusion
Normalized name: Maytenus krukovii bark extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g of powdered leaves in 150 mL of boiling water, 3 times a day, for 8 weeks
Study: NCT00004440
Drug: ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02395978
Drug: PDC-1421 Capsule
Normalized name: chlorpheniramine maleate / dihydrocodeine bitartrate / phenylephrine hydrochloride Oral Solution [Despec-PDC]
Approvals — FDA: no, EMA: no, PMDA: no
Description: PDC-1421 Capsule is a botanical investigational new drug containing the extract of Radix Polygalae (Polygala tenuifolia Willd.) as active ingredient.
Study: NCT02395978
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo contained corn starch.
Study: NCT00048412
Drug: CAMPATH 1H
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02238210
Drug: Atrovent®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03324035
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administer amitriptyline on flexible doses variating from 1 to 3 capsules, with backup of tramadol, and evaluate the reduction of the pain based on the Brief Pain Inventory Questionnaire.
Study: NCT03287791
Drug: Finacea® (Azelaic Acid) Foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical foam, brand product.
Study: NCT00828243
Drug: Nutrient
Normalized name: Nutrients
Approvals — FDA: no, EMA: no, PMDA: no
Description: We administer stable isotopically labeled precursors of surfactant phospholipids (\[1-13C1\] acetate) and of surfactant protein-B (\[5,5,5-2H3\] leucine) to infants with neonatal respiratory distress syndrome. Using mass spectrometry, we measure incorporation of stable isotopically labeled precursors in tracheal aspirates and compare surfactant phospholipid and surfactant protein-B turnover.
Study: NCT01568073
Drug: BIA 9-1067
Normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5, 25 and 50 mg of BIA 9-1067 (once-daily)
Study: NCT03811574
Drug: Placebo (semaglutide)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (semaglutide) injections will be administered once-weekly by a pre-filled pen-injector at the same day of the week (to the extent possible). Injections may be administered in the thigh, abdomen or upper arm, at any time of day irrespective of meals.
Study: NCT02137863
Drug: 0.9 % NaCl
Normalized name: dextrose 10 %-0.9 % NaCl MISCELL LIQUID (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: During 12 hours before the procedure 3 ml/kg/h 0.9 % NaCl infusion and 1 ml/kg/h during the angioplasty and 12 hours after the procedure.
Study: NCT02137863
Drug: 0.9 % NaCl
Normalized name: dextrose 10 %-0.9 % NaCl MISCELL LIQUID (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 ml/10min infusion just before the angiography~1 ml/kg/h infusion during the angiography and was continued 12 hours after the procedure
Study: NCT03845127
Drug: GDMT
Normalized name: Guideline-Directed Medical Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline Directed Medical Therapy
Study: NCT01381016
Drug: Estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects were instructed to apply 0.1 mg/d transdermal estrogen for one month.
Study: NCT00333008
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00121563
Drug: Thalidomide, Ibuprofen or Diazepam
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04924062
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to pembrolizumab
Study: NCT04319874
Drug: Ganoderma lucidum
Normalized name: GANODERMA LUCIDUM STEM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants take ganoderma lucidum spore powder once a day, 1000mg
Study: NCT04319874
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects are treated with conventional chemotherapy
Study: NCT04319874
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects are treated with conventional chemotherapy and Placebos once a day, 1000mg
Study: NCT03083197
Drug: Doxycycline 7 days
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: loading dose 200mg PO, then 100mg PO every 12 hours for 7 days
Study: NCT03083197
Drug: Doxycycline 3 days
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: loading dose 200mg PO, then 100mg PO every 12 hours for 3 days
Study: NCT03083197
Drug: Azithromycin 3 days
Approvals — FDA: no, EMA: no, PMDA: no
Description: loading dose 1000mg PO on day 1, then 500mg PO every 24 hours on days 2 and 3
Study: NCT02886286
Drug: Opioid
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-activated intrathecal bolus for incident pain
Study: NCT00891436
Drug: Placebo nasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 sprays each nostril every morning for 2 weeks
Study: NCT02290613
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet (one to two tablets corresponding to one to two verum tablets)
Study: NCT02734849
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered as multiple doses
Study: NCT00744224
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of placebo with saline infusion
Study: NCT00744224
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single dose of 80 mg prednisolone with saline infusion
Study: NCT00744224
Drug: Prednisolone and Exenatide
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone 80 mg single dose Exenatide infusion 20 mg/min
Study: NCT02616068
Drug: Transdermal Patch
Normalized name: TRANSDERMAL PATCH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal patch 100 mg once a day for 7 days
Study: NCT02616068
Drug: Placebo (for transdermal patch)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (for transdermal patch 100 mg) once a day for 7 days
Study: NCT06235424
Drug: Del Nido Cardioplegia Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: The route of cardioplegia delivery differed according to surgeons' preferences. The total dosage of cardioplegia depends on the type of cardioplegia. The standard dose of del Nido cardioplegia in our institution is 1000 ml as an initial dose and is delivered with a system pressure of 90-150 mmHg. The solution is prepared by our hospital's pharmacy. At 60. minute of cross-clamp (XC) if XC time was expected to exceed 90 minutes another dose of solution would be delivered. The volume of an additional dose was 500 ml. The temperature of the delivered del Nido cardioplegia was 4\*C.
Study: NCT06235424
Drug: HTK solution
Normalized name: Custodial HTK Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: The route of cardioplegia delivery differed according to surgeons' preferences. The dose of the HTK cardioplegia is calculated with an application of 20 mL/kg rule. It is delivered with a system pressure of 90-150 mmHg. If the XC time exceeds 120 minutes additional dose is given (10 mL/kg rule). The temperature of the delivered crystalloid cardioplegia is 4\*C
Study: NCT03098368
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo of rotigotine patch
Study: NCT02699385
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each participants will receive placebo oral suspension thrice daily for up to 7 days.
Study: NCT02539225
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV
Study: NCT01086982
Drug: Sandostatin LAR ® (octreotide acetate LAR) 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg, single dose
Study: NCT01472003
Drug: ABT-806
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-806 will be administered by intravenous infusion.
Study: NCT01472003
Drug: ABT-806i
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-806i will be administered by intravenous infusion.
Study: NCT00928213
Drug: Low molecular weight Heparin
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40-80 mg/day
Study: NCT00928213
Drug: No Drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: no treatment
Study: NCT01071369
Drug: Xylocaine and Celestone
Approvals — FDA: no, EMA: no, PMDA: no
Description: non-particulate Celestone
Study: NCT02098148
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01934959
Drug: Bifico
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00942565
Drug: tramadol/acetaminophen
Normalized name: TRAMADOL/ACETAMINOPHEN
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00942565
Drug: acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03527836
Drug: Mixture brachial plexus block
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined Axillary-supraclavicular approach to brachial plexus with mixture solution of 20 ml bupivacaine 0.5% and 10 ml lidocaine 1%
Study: NCT02576093
Drug: 0.1% WOL071-007
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application of approximately 2 mg cream/cm² skin to a defined surface area. SAD part: Single application to ≤ 100 cm² of non-lesional or lesional skin; MAD part: Multiple application (6 Days) to 2000 cm² of lesional and non-lesional skin.
Study: NCT02576093
Drug: 0.3% WOL071-007
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application of approximately 2 mg cream/cm² skin to a defined surface area. SAD part: Single application to ≤ 100 cm² of non-lesional or lesional skin; MAD part: Multiple application (6 Days) to 2000 cm² of lesional and non-lesional skin.
Study: NCT02576093
Drug: 1.0% WOL071-007
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application of approximately 2 mg cream/cm² skin to a defined surface area. SAD part: Single application to ≤ 100 cm² of non-lesional or lesional skin; MAD part: Multiple application (6 Days) to 2000 cm² of lesional and non-lesional skin.
Study: NCT02576093
Drug: Placebo of WOL071-007
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application of approximately 2 mg cream/cm² skin to a defined surface area. SAD part: Single application to ≤ 100 cm² of non-lesional or lesional skin; MAD part: Multiple application (6 Days) to 2000 cm² of lesional and non-lesional skin.
Study: NCT01960192
Drug: HD-MTX-Ara-C regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: high-does metrotrexate 3.5g/m2 d1 ivgtt 6h,cytarabine 1g/m2 bid d2-3.Continued use to the end of chemotherapy .Every 21 days for one cycle and four cycles are required. Efficacy was evaluated every two cycles
Study: NCT01960192
Drug: FVD regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: FVD regimen(fotemustine, teniposide and dexamethasone),fotemustine 100mg/m2 d1 ivgtt,teniposide 60mg/m2 d2-4 ivgtt,dexamethasone 40mg d1-5 ivgtt.Continued use to the end of chemotherapy .Every 21 days for one cycle and four cycles are required. Efficacy was evaluated every two cycles
Study: NCT00414856
Drug: AFQ056
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02544152
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo, 0 mcg administered orally twice daily (BID)
Study: NCT01071291
Drug: Comparator: Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo